Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDX3X | O00571 | 2/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.55 |
| ▸ | RELA | Q04206 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28877258 | 0.89 | ALDH1A1 (0.57) | DDX3XALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL18311596 | 0.89 | DDX3X (0.70) | DDX3XALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL1657499 | 0.85 | DDX3X (1.00) | DDX3XALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL30314470 | 0.85 | DDX3X (1.00) | DDX3XALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL6782639 | 0.84 | BTK (0.64) | DDX3XALDH1A1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL16488794 | 0.82 | MAPT (0.56) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL18311495 | 0.81 | MAPT (0.62) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL29356607 | 0.80 | MAPT (0.57) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL33898 | 0.80 | MAPT (0.57) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL30469233 | 0.80 | MAPT (0.75) | MAPTMEN1KMT2ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10351522-B2 | Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof | UNIVERSITY OF TSUKUBA (JP) | 2019-07-16 | — | — | US | disclosed |
| US-20180179151-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | UNIVERSITY OF TSUKUBA (JP) | 2018-06-28 | — | — | US | disclosed |
| EP-3309146-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | University of Tsukuba (JP) | 2018-04-18 | — | — | EP | disclosed |
| WO-2016199906-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | 国立大学法人筑波大学 | 2016-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179151-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | HCRTR2, HCRTR1, NPSR1 | DDX3X 3422/4885ALDH1A1 968/4885MAPT 1919/4885 |
| US-10351522-B2 | Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof | HCRTR2, HCRTR1, NPSR1 | DDX3X 3422/4885ALDH1A1 968/4885MAPT 1919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.